The NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab.

The NG2-ITGA4 axis promotes leukemic aggressiveness in KMT2A-r B-ALL and can be targeted with natalizumab.

• Why it matters: KMT2A-r B-ALL is an aggressive leukemia subtype with high relapse rates and poor long-term survival, especially after existing CD19-targeted therapies. Understanding its molecular drivers is crucial for developing new treatments.
• What they did: Researchers identified NG2 and ITGA4 as key contributors to leukemia progression, showing that NG2 promotes cell proliferation and migration through Rho GTPase activity dependent on ITGA4, and demonstrated that natalizumab delays disease progression in mouse models.
• The result: Targeting the NG2-ITGA4 axis with natalizumab significantly delays leukemia progression and enhances chemotherapy efficacy, suggesting its potential as an adjuvant therapy for high-risk KMT2A-r B-ALL.